Champlain Investment Partners LLC Acquires 191,215 Shares of Veracyte, Inc. (NASDAQ:VCYT)

Champlain Investment Partners LLC raised its holdings in Veracyte, Inc. (NASDAQ:VCYTGet Rating) by 12.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,767,500 shares of the biotechnology company’s stock after acquiring an additional 191,215 shares during the quarter. Champlain Investment Partners LLC’s holdings in Veracyte were worth $72,821,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Teachers Retirement System of The State of Kentucky grew its position in Veracyte by 95.6% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 24,994 shares of the biotechnology company’s stock valued at $1,161,000 after acquiring an additional 12,219 shares during the last quarter. Clough Capital Partners L P grew its position in shares of Veracyte by 12.9% during the 3rd quarter. Clough Capital Partners L P now owns 256,060 shares of the biotechnology company’s stock worth $11,894,000 after buying an additional 29,200 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Veracyte by 5.6% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,121,103 shares of the biotechnology company’s stock worth $128,589,000 after buying an additional 164,724 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Veracyte by 4.0% during the 4th quarter. ProShare Advisors LLC now owns 24,731 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 945 shares in the last quarter. Finally, FDx Advisors Inc. bought a new position in shares of Veracyte during the 4th quarter worth $244,000.

VCYT stock traded up $1.03 during trading on Thursday, hitting $16.48. 1,881,782 shares of the company traded hands, compared to its average volume of 918,261. The stock’s 50-day simple moving average is $24.45 and its 200 day simple moving average is $32.46. The company has a market cap of $1.18 billion, a PE ratio of -24.15 and a beta of 1.11. Veracyte, Inc. has a 1 year low of $14.85 and a 1 year high of $54.13.

Veracyte (NASDAQ:VCYTGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. Veracyte had a negative return on equity of 4.09% and a negative net margin of 19.22%. During the same quarter in the previous year, the company earned ($0.11) earnings per share. Research analysts predict that Veracyte, Inc. will post -0.77 earnings per share for the current year.

In related news, insider Giulia C. Kennedy sold 23,003 shares of Veracyte stock in a transaction that occurred on Friday, March 4th. The stock was sold at an average price of $25.12, for a total transaction of $577,835.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.90% of the stock is currently owned by company insiders.

A number of equities analysts have recently issued reports on VCYT shares. Lake Street Capital dropped their price target on Veracyte from $95.00 to $50.00 in a research report on Tuesday, March 1st. StockNews.com started coverage on Veracyte in a research report on Thursday, March 31st. They set a “sell” rating on the stock. SVB Leerink dropped their price target on Veracyte from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 1st. Zacks Investment Research raised Veracyte from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. Finally, TheStreet cut Veracyte from a “c-” rating to a “d+” rating in a research note on Tuesday, January 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Veracyte presently has an average rating of “Buy” and a consensus price target of $43.78.

About Veracyte (Get Rating)

Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.

Recommended Stories

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYTGet Rating).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.